Keith is a co-lead investigator on a project to develop rapid response vaccine pipeline. Rapid vaccine development is based on a novel, broadly applicable platform technology, the molecular clamp, which facilitates the expression of recombinant viral glycoproteins in subunit form without loss of native antigenicity. UQ has received $14.7M in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to establish a rapid response vaccine involving a consortium of Australia’s leading scientific organisations and capable of completing pre-clinical development, animal toxicology studies, CMC-manufacture and Phase I clinical trials, within an expedited time scale.